HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a 'Buy' rating on Acrivon Therapeutics (NASDAQ:ACRV), but lowered the price target from $21 to $20.
August 11, 2023 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Acrivon Therapeutics' price target has been lowered from $21 to $20 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The news is directly about Acrivon Therapeutics and is likely to influence investor sentiment. The lowered price target may suggest a slightly less optimistic outlook, but the maintained 'Buy' rating indicates that the analyst still sees potential in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100